ArticleAnnals of gastroenterological surgery2026
Preoperative Gemcitabine/Nab-Paclitaxel With Concurrent Radiation Therapy for Borderline Resectable Pancreatic Cancer: A Comparative Analysis With Preoperative Chemoradiation Therapy Using Gemcitabine Alone.
Article in Annals of gastroenterological surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
- Erratum issued
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Although NCCN guidelines recommend preoperative therapy for borderline resectable pancreatic cancer (BR-PC), it is still unclear which regimen is better. The study objective was to elucidate the prognostic significance of neoadjuvant chemoradiotherapy (NACRT) with gemcitabine/nab-paclitaxel (GnP-RT) compared to gemcitabine alone (Gem-RT) in BR-PC. Methods: Of 201 patients with BR-PC enrolled in the study, 102 were receiving GnP-RT and 99 were receiving Gem-RT. We evaluated clinical outcomes between these two groups, including CA19-9 values, rate of tumor reduction, overall (OS) and progression-free survival (PFS) rates, and distant and local recurrence. Results: CA19-9 values and tumor size reduction rate after NACRT were significantly higher with GnP-RT than with Gem-RT. With GnP-RT, the 5-year OS rate was 55.2% and the PFS rate was 42.1%, both significantly better than rates with Gem-RT (OS, 35.4%, Conclusion: Enhanced chemotherapy may improve survival in patients with BR-PC by suppressing distant metastasis through a potent systemic antitumor effect.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.